{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:57:38Z","timestamp":1792803458906,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203331"],"award-info":[{"award-number":["NIHR203331"]}],"id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1136\/ard-2024-226429","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T02:15:11Z","timestamp":1731032111000},"page":"77-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis"],"prefix":"10.1016","volume":"84","clinical-trial-number":[{"clinical-trial-number":"nct02583789","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alain","family":"Lescoat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Bertoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"\u010coli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossra A.","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Emmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco del","family":"Galdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-226429_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"The Lancet"},{"key":"10.1136\/ard-2024-226429_bib0002","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-226429_bib0003","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2665-9913(19)30038-4","article-title":"The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder","volume":"1","author":"Lescoat","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-226429_bib0004","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226429_bib0005","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-226429_bib0006","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226429_bib0007","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226429_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic Sclerosis\u2013Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration\u2013Approved Therapies in Clinical Practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis & Rheumatology"},{"key":"10.1136\/ard-2024-226429_bib0009","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis- Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226429_bib0010","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2665-9913(21)00111-9","article-title":"Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis","volume":"3","author":"Denton","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-226429_bib0011","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-226429_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-226429_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2022.6340","article-title":"Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels","author":"Kuzumi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1136\/ard-2024-226429_bib0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-226429_bib0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5301\/jsrd.5000216","article-title":"Limited cutaneous systemic sclerosis: the unfairly neglected subset","volume":"1","author":"Allanore","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1136\/ard-2024-226429_bib0016","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez435","article-title":"Classifications of scleroderma renal crisis and reconsideration of its pathophysiology","volume":"58","author":"Yamashita","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-226429_bib0017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator\u2010Initiated, Multicenter, Double\u2010Blind, Randomized, Placebo\u2010Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226429_bib0018","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-226429_bib0019","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-226429_bib0020","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the Treatment of Pulmonary Arterial Hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226429_bib0021","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226429_bib0022","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226429_bib0023","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226429_bib0024","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-226429_bib0025","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo- controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226429_bib0026","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo- controlled Trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/ard-2024-226429_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/2397198320961967","article-title":"Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes","volume":"6","author":"Lescoat","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1136\/ard-2024-226429_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.11.003","article-title":"Symptom experience of limited cutaneous systemic sclerosis from the Patients\u2019 perspective: A qualitative study\u2730,\u2730\u2730,\u2605,\u2605\u2605","volume":"52","author":"Lescoat","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2024-226429_bib0029","article-title":"Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region","author":"Lescoat","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"10.1136\/ard-2024-226429_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac405","article-title":"Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model","volume":"62","author":"Garaiman","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-226429_bib0031","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226429_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002477","article-title":"Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort","volume":"8","author":"Kuster","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-226429_bib0033","first-page":"2737","article-title":"Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative: ACR\/EULAR Classification Criteria for SSc","volume":"65","author":"Hoogen","year":"2013","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724148467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724148467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-226429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T21:31:32Z","timestamp":1740519092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724148467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0003496724148467"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-226429","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-226429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-226430","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}